scholarly journals Mechanism, Diagnosis, Medication, Care Guidance, and Health Promotion in Alzheimer’s Disease

2020 ◽  
Vol 218 ◽  
pp. 03047
Author(s):  
Dong Yue
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Care ◽  
Health Promotion ◽  
Daily Activity ◽  
Memory Loss ◽  
Review Article ◽  
Peptide Aggregation ◽  
Aβ Peptide ◽  
Medical Conditions

Alzheimer’s Disease (AD) is one of the most serious and prevalent medical conditions, manifested by memory loss and daily activity dysfunction. Many established hypotheses regarding AD, such as Aβ peptide aggregation and tau tanglements, have provided a fundamental basis. Despite the progress, AD still possesses irreversibility, and the current treatments generated towards AD only aimed to slow down progression. Therefore, further studies on AD mechanism, diagnosis, medication, care guidance, health care and health promotion are constantly conducted for enhancement and advancement. This review article briefly demonstrates long-established facts and sums up the recent discoveries on AD.

scholarly journals Anti-Aggregation Property of Allicin by In Vitro and Molecular Docking Studies

2019 ◽  
Vol 13 ◽  
pp. 117906951986618 ◽  
Author(s):  
Suresh Kumar ◽  
Shivani Kumar ◽  
Heera Ram
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Docking ◽  
Molecular Interaction ◽  
Fibril Formation ◽  
Amyloid Peptide ◽  
Peptide Aggregation ◽  
Aβ Peptide ◽  
In Silico Studies

Amyloidogenesis is the process in which amyloid beta (Aβ) peptide aggregation results in plaque formation in central nervous system (CNS) are associated with many neurological diseases such as Alzheimer’s disease. The peptide aggregation initiated from peptide monomers results in formation of dimers, tetramers, fibrils, and protofibrils. The ability of allicin, a lipid-soluble volatile organosulfur biological compound, present in freshly crushed garlic ( Allium sativum L.) to inhibit fibril formation by the Aβ peptide in vitro was investigated in the present study. Inhibition of fibrillogenesis was measured by a Thioflavin T (ThT) fluorescence assay and visualized by transmission electron microscopy (TEM). The molecular interaction between allicin and Aβ peptide was also demonstrated by in silico studies. The results show that allicin strongly inhibited Aβ fibrils by 97% at 300 µM, compared with control (Aβ only) ( P < .001). These results were further validated by visual of fibril formation by transmission microscopy and molecular interaction of amyloid peptide with allicin by molecular docking. Aβ forms favourable hydrophobic interaction with Ile32, Met35, Val36, and Val39, and oxygen of allicin forms hydrogen bond with the amino acid residue Lys28. Allicin anti-amyloidogenic property suggests that this naturally occurring compound may have potential to ameliorate and prevent Alzheimer’s disease.

scholarly journals Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease

2017 ◽  
Vol 8 (8) ◽  
pp. 5636-5643 ◽  
Author(s):  
Michael R. Jones ◽  
Emilie Mathieu ◽  
Christine Dyrager ◽  
Simon Faissner ◽  
Zavier Vaillancourt ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Agents ◽  
Peptide Aggregation ◽  
Primary Neurons ◽  
Aβ Peptide

A series of multi-target-directed ligands are described that bind Cu, act as antioxidants, modulate Aβ peptide aggregation, and abolish Aβ toxicity in primary neurons.

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Nature ◽  
2000 ◽  
Vol 408 (6815) ◽  
pp. 982-985 ◽  
Author(s):  
Dave Morgan ◽  
David M. Diamond ◽  
Paul E. Gottschall ◽  
Kenneth E. Ugen ◽  
Chad Dickey ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Animal Model ◽  
Memory Loss ◽  
Aβ Peptide ◽  
Peptide Vaccination ◽  
Model Of Alzheimer’S Disease

scholarly journals “Making Sense of a Disease That Makes No Sense”: Understanding Alzheimer’s Disease and Related Disorders Among Caregivers and Providers Within Alaska Native Communities

2020 ◽  
Author(s):  
Jordan P Lewis ◽  
Spero M Manson ◽  
Valarie B Jernigan ◽  
Carolyn Noonan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Care ◽  
Support Groups ◽  
Health Care Providers ◽  
Alaska Native ◽  
Adult Population ◽  
Memory Loss ◽  
Cost Of Care ◽  
Care Providers

Abstract Background and Objectives With the rate of Alzheimer’s disease and related dementias (ADRD) increasing among Alaska Indian/Alaska Native (AI/AN) people, the Alaska Native Health system is ill-prepared to meet the challenges associated with the growing population at risk of ADRD. The high cost of care, inadequate training of health care providers, and lack of supportive services for caregivers are especially concerning. Research Design and Methods Interviews were conducted with 22 AN caregivers for ANs with ADRD and 12 ANs and non-Native health care providers in communities across Alaska. Interviews lasted approximately 60 min and were transcribed verbatim. We employed directed content analysis to examine the major agreements and disagreements between the participants’ understandings of ADRD in each of the domains of Kleinman’s Explanatory Model of Illness. Results Caregivers and health care providers expressed concerns about the lack of understanding, resources, and awareness of ADRD among ANs in rural and urban communities. Both caregivers and providers recognized the need to obtain an early diagnosis, blend Western and traditional medicines, promote lifestyle and dietary changes, and foster training for caregivers. Health care providers acknowledged their limited exposure to AN understanding of ADRD and wish to receive culturally relevant training to better serve AN. Discussion and Implications As the older AN adult population grows, the need for culturally responsive training and support services will continue to increase. We recommend establishing rural outreach and support groups for caregivers, developing an understanding of how ANs view ADRD to train and educate health care providers, and implement screening early for memory loss during routine medical examinations.

scholarly journals Erratum: correction: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Nature ◽  
2001 ◽  
Vol 412 (6847) ◽  
pp. 660-660 ◽  
Author(s):  
Dave Morgan ◽  
David M. Diamond ◽  
Paul E. Gottschall ◽  
Kenneth E. Ugen ◽  
Chad Dickey ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Animal Model ◽  
Memory Loss ◽  
Aβ Peptide ◽  
Peptide Vaccination ◽  
Model Of Alzheimer’S Disease

scholarly journals A Global Review on Alzheimer’s Disease

2021 ◽  
Vol 68 (1) ◽  
Author(s):  
Natarajan. P ◽  
Mumthaj. P ◽  
Vijay. J ◽  
Gokul. V
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinesterase Inhibitors ◽  
Genetic Factors ◽  
Environmental Changes ◽  
Late Onset ◽  
Memory Loss ◽  
Review Article ◽  
Acetyl Cholinesterase ◽  
Alois Alzheimer

Alzheimer’s disease (AD) is an inevitable neurological disorder in which the death of brain cells causes memory loss and cognitive decline and ultimate dementia. It’s the foremost common cause of dementia in people of 65 years and older. It was first described by a neurologist Alois Alzheimer in 1906. This review article gives an account on the various symptoms from pre-dementia to severe Alzheimer’s dementia. The Alzheimer’s disease is caused by the pathogenesis by accumulation of toxic amyloid-? plaques (A?) and Hyper phosphorylated tau (p-tau). The greatest risk factors for late onset Alzheimer’s are age, genetics, family history and non-genetic factors (heart health, life style modifications, and environmental changes). The diagnosis of AD advances in genetics, the event of biomarkers of neuro degeneration and neuroimaging discovery utilizes the method to detect AD. The medication use to treat AD is acetyl cholinesterase inhibitors and N-methyl D aspartate antagonists and various drugs are under clinical trials.

Recent Progress on the Drug Development for the Treatment of Alzheimer’s Disease Especially on Inhibition of Amyloid-Peptide Aggregation

2020 ◽  
Vol 20 ◽  
Author(s):  
Yuanyuan Liu ◽  
Lin Cong ◽  
Chu Han ◽  
Bo Li ◽  
Rongji Dai
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Amyloid Peptide ◽  
Research Progress ◽  
Peptide Aggregation ◽  
Aβ Peptide ◽  
Design And Synthesis ◽  
Aggregation Inhibitors ◽  
The Brain

: As the world's population is ageing, Alzheimer’s disease (AD) has become a big concern since patients suffering from AD have become younger and the population of AD patients is increasing worldwide. It has been revealed that the neuropathological hallmarks of AD are typically characterized by the presence of neurotoxic extracellular amyloid plaques in the brain, which are surrounded by tangles of neuronal neuronal fibers. However, the causes of AD have not been completely understood yet. Currently, there is no drug to effectively prevent AD or to completely reserve the symptoms in the patients. This article reviews the pathological features associated with AD, the recent research progress on the drug development to treat AD especially on discovery of natural product derivatives to inhibit Aβ peptide aggregation as well as design and synthesis of Aβ peptide aggregation inhibitors to treat AD.

scholarly journals AN ASSESSMENT OF GERIATRIC TTRAINING AND SUPPORT NEEDS FOR CAREGIVERS AND HEALTH CARE PROFESSIONALS IN RURAL TEXAS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S931-S932
Author(s):  
Susanna Luk-Jones ◽  
Jennifer J Severance ◽  
Doni Green ◽  
Donald Smith ◽  
Roslin Jose
Keyword(s):  
Alzheimer’S Disease ◽  
Older Adults ◽  
Alzheimer's Disease ◽  
Health Care ◽  
Memory Loss ◽  
Support Needs ◽  
Evidence Based ◽  
Rural Counties ◽  
Evidence Based Programs ◽  
With Memory

Abstract Of the 254 counties in Texas, 69% are rural, and three out of every four counties are designated as whole or partial Primary Care Health Professional Shortage Areas. Rural counties in Texas have a higher proportion of older adults compared to metropolitan counties, and rural older adults with Alzheimer’s Disease and their caregivers face unique challenges of limited access to healthcare and lower earnings, resulting in more health-related problems. As part of a HRSA Geriatrics Workforce Enhancement Program, an academic medical center, two Area Agencies on Aging in North Texas, and an Alzheimer’s Association Chapter partnered to expand access to evidence-based programs into surrounding rural counties for older adults and caregivers of persons with Alzheimer’s Disease. An interdisciplinary workgroup developed focus group questionnaires for older adults, caregivers, and health care providers in rural areas to identify perceived needs, barriers to accessing services, and strategic partnerships. The North Central Texas Council of Governments conducted 11 focus groups in late 2018 and early 2019. Of these, seven consisted of family members caring for persons with memory loss. Four consisted of professionals who treat persons with memory loss. Transcription and thematic analysis identified key themes of training needs (both providers’ and laypersons’), resource needs, providers’ best practices, barriers to quality care, and other support needs. Practice implications of the findings include cross-sector partners and integrating telehealth platforms for program delivery. Collaboration between academic and community partners can expand access to evidence-based programs for rural and other underserved communities and address areas of need.

scholarly journals Potential microRNA-related targets in clearance pathways of amyloid-β: novel therapeutic approach for the treatment of Alzheimer’s disease

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Soheil Madadi ◽  
Heidi Schwarzenbach ◽  
Massoud Saidijam ◽  
Reza Mahjub ◽  
Meysam Soleimani
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Peptide Synthesis ◽  
Amyloid Β ◽  
Review Article ◽  
Signal Pathways ◽  
Aβ Peptide ◽  
Biological Processes ◽  
Aβ Clearance ◽  
Novel Therapeutic

Abstract Imbalance between amyloid-beta (Aβ) peptide synthesis and clearance results in Aβ deregulation. Failure to clear these peptides appears to cause the development of Alzheimer’s disease (AD). In recent years, microRNAs have become established key regulators of biological processes that relate among others to the development and progression of neurodegenerative diseases, such as AD. This review article gives an overview on microRNAs that are involved in the Aβ cascade and discusses their inhibitory impact on their target mRNAs whose products participate in Aβ clearance. Understanding of the mechanism of microRNA in the associated signal pathways could identify novel therapeutic targets for the treatment of AD.

Sign in / Sign up

Export Citation Format

Share Document